Search research articles
Contact Us
Filters
Showing results (1-10 of 20) with videos related to
Page
of 2
Sort By:
Cancer Chemotherapy and Pharmacology
|
November 8, 2005
Chemotherapy for prostate cancer: implementing early systemic therapy to improve outcomes
Gary R Macvicar, Maha Hussain
Current Opinion in Oncology
|
March 21, 2013
Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer
Gary R MacVicar, Maha H Hussain
Current Opinion in Oncology
|
April 8, 2004
Testicular cancer
Gary R MacVicar, Kenneth J Pienta
Archives of Pathology & Laboratory Medicine
|
January 11, 2012
Predictors of response to targeted therapy in renal cell carcinoma
Laurie J Eisengart, Gary R MacVicar, Ximing J Yang
Tumori
|
June 11, 2013
Using intensity-modulated radiotherapy to spare the kidney in a patient with seminoma and a solitary kidney: a case report
Mehee Choi, John P Hayes, Minesh P Mehta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 26, 2026
Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.1
Lyudmila Bazhenova, Nofisat Ismaila, Greg Durm, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 15, 2014
Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer
Robert Dreicer, David MacLean, Ajit Suri, et al.
Cancer Research
|
December 18, 2004
Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program
Rajal B Shah, Rohit Mehra, Arul M Chinnaiyan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2007
Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial
Maha H A Hussain, Gary R MacVicar, Daniel P Petrylak, et al.
The Oncologist
|
April 19, 2022
Phase II Clinical and Translational Study of Everolimus ± Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma
Tomi Jun, Noah M Hahn, Guru Sonpavde, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 20) with videos related to
Sort By:
Page
of 2
Cancer Chemotherapy and Pharmacology
|
November 8, 2005
Chemotherapy for prostate cancer: implementing early systemic therapy to improve outcomes
Gary R Macvicar, Maha Hussain
Current Opinion in Oncology
|
March 21, 2013
Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer
Gary R MacVicar, Maha H Hussain
Current Opinion in Oncology
|
April 8, 2004
Testicular cancer
Gary R MacVicar, Kenneth J Pienta
Archives of Pathology & Laboratory Medicine
|
January 11, 2012
Predictors of response to targeted therapy in renal cell carcinoma
Laurie J Eisengart, Gary R MacVicar, Ximing J Yang
Tumori
|
June 11, 2013
Using intensity-modulated radiotherapy to spare the kidney in a patient with seminoma and a solitary kidney: a case report
Mehee Choi, John P Hayes, Minesh P Mehta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 26, 2026
Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.1
Lyudmila Bazhenova, Nofisat Ismaila, Greg Durm, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 15, 2014
Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer
Robert Dreicer, David MacLean, Ajit Suri, et al.
Cancer Research
|
December 18, 2004
Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program
Rajal B Shah, Rohit Mehra, Arul M Chinnaiyan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2007
Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial
Maha H A Hussain, Gary R MacVicar, Daniel P Petrylak, et al.
The Oncologist
|
April 19, 2022
Phase II Clinical and Translational Study of Everolimus ± Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma
Tomi Jun, Noah M Hahn, Guru Sonpavde, et al.
Page
of 2